



New Major Asthma Partnership with US-Based SENTA Partners

- **Hailie® platform becomes available to SENTA clinics and patients**
- **Hailie provides real-time data for patient feedback for self-management and improved health outcomes**
- **Enables doctors to bill for remote patient management, generating repeat multi-year revenues**
- **SENTA roll out plan finalised as Adherium builds US implementation team**

Melbourne, Australia – 18 September 2023: Adherium Limited (ASX: ADR), a leading digital health company specialising in remote patient monitoring and data solutions for respiratory patients, confirms a new transformative partnership in which SENTA Partners has agreed on a plan to roll out the Hailie platform to its base of clinics and patients across their network.

SENTA (Southern Ear, Nose, Throat and Allergy) is one of the largest, premier specialty allergy and asthma groups in the United States. Headquartered in Atlanta, Georgia, SENTA boasts a network of 48 locations in six states with 88 allergy, asthma and ENT physicians, physician assistants and nurse practitioners.

Adherium and SENTA Partners have prepared an implementation plan commencing this month with an initial rollout in Georgia under direction of a lead physician, practice administrator and nurse practitioner. To support SENTA's rollout Adherium is investing in and building up the US implementation team including clinical applications, technical support and customer service staff. Expansion to additional SENTA clinic locations is planned for later this calendar year. With sufficient US sensor inventory and a responsive contract manufacturer, Adherium is fully prepared to meet the expected growing demand.

"This important partnership marks another US commercialisation milestone as we strive to rapidly build large-scale product roll out. We are committed to our partner's success and as such are investing with US-based, on-the-ground implementation staff

to execute and achieve our commercial objectives under our partner agreements.

Together, Adherium and SENTA Partners aim to make a profound impact on improving patients' lives and respiratory care," commented Rick Legleiter, CEO of Adherium.

Under this strategic alliance SENTA Partners will leverage Adherium's advanced Hailie platform to improve adherence and inhaler technique for its asthma patients with emphasis on the latest generation of Adherium devices that monitor patient inspiratory flow.

Hailie enables doctors to bill for long-term, remote patient management under established US reimbursement codes. Adherium gets paid for sensor sales and by receiving monthly, per patient fees for generating and transmitting respiratory data.

The Hailie platform, comprising leading-edge sensor technology, a user-friendly app, clinician portal and cloud-based data solution, helps patients to actively manage their asthma conditions. It equips healthcare providers with valuable data that supports medication adherence, behavioral interventions, and personalised treatments while enabling remote patient monitoring billing.

Hailie's cloud-based platform captures and shares data from Bluetooth-enabled sensors attached to prescribed inhalers. These clinically proven sensors provide critical insights into when and how inhalers are used, significantly improving adherence and patient management. This facilitates timely interventions and tailored treatments, leading to improved health outcomes and greatly reduce hospital admissions.

Following four US FDA 510(k) market clearances of the next generation Hailie sensors, Adherium progressed on its regulatory strategy to 79% coverage for sensors capturing physiological data such as inhalation flow rate, and 91% coverage for adherence tracking of US top 20 branded inhaler medications by sales volume. Hailie is the only FDA 510(k) cleared drug agnostic digital sensor available that offers physiological data insights on inhaler technique.

For more information about Adherium and Hailie, visit www.adherium.com.

This ASX announcement was approved and authorised for release by the Adherium Board of Directors.

Enquiries:

Rick Legleiter
CEO
Adherium Limited
investors@adherium.com

Rudi Michelson
Monsoon Communications
rudim@monsoon.com.au

-ENDS-

About Adherium

Adherium Limited (ASX: ADR) is a digital health company providing solutions for improving patient treatment with remote monitoring and data solutions. Its Hailie® system is transforming management of chronic respiratory conditions, especially asthma and chronic obstructive pulmonary disease. Hailie improves patient health through better adherence and self-management while enabling doctors to be paid for remote work and saving costs across health systems by avoiding hospital admissions. Adherium's clinically proven sensors, app and powerful data platform provide remote, real-time, personalised information to patients and clinicians. Adherium is increasing sales in US, UK and other markets by pursuing partnerships with major hospital systems, medical groups and insurers. For more information, visit <https://www.adherium.com/>

About the Hailie Platform

Adherium's proprietary Hailie® platform is transforming the management of chronic respiratory conditions including asthma and chronic obstructive pulmonary disease.

Hailie's cloud-based platform captures and shares information from Bluetooth enabled sensors that wrap around a patient's prescribed inhaler. With a user-friendly app, a patient can receive, act on and share their personal information and data reports with doctors and carers.

Hailie's growing portfolio of sensors have been cleared by the FDA and approved by the TGA, EU and UK. The clinically proven sensors remotely capture when and how an inhaler is being used through key physiological parameters including inhalation flow rate, anywhere people live, work and study.

The Hailie solution creates and delivers data supporting far better patient medication adherence, behavioural influencing, escalations and interventions to improve health outcomes and self-management by patients. The Hailie platform drives health costs down by reducing hospital admissions and enables doctors to bill for remote patient management.

Independent studies show the Hailie platform increases medication adherence by 180% in children with an associated 80% reduction in hospital admissions. Hailie has been shown to increase adherence by 59% in adults with a reduction in severe exacerbations of 61%.

About SENTA Partners:

SENTA Partners (Southern Ear, Nose, Throat and Allergy) is one of the largest and most prominent allergy and asthma practices in the United States. With headquarters in Atlanta, Georgia, SENTA Partners operates across 48 locations in 6 states, staffed by 88 dedicated healthcare professionals, including physicians, physician assistants, and nurse practitioners. Committed to delivering exceptional medical expertise, patient-centered care, and innovative solutions, SENTA Partners serves individuals with respiratory, allergy and ENT conditions, striving to improve their quality of life.